证券代码：002365 证券简称：永安药业 公告编号：2025-52 潜江永安药业股份有限公司 关于购买理财产品的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 潜江永安药业股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日、2025 年 6 月 24 日分别召开了第七届董事会第六次临时会议及 2024 年年度股东会，审 议通过了《关于使用自有资金进行委托理财的议案》，同意公司及子公司总计使 用最高额度不超过（含）人民币 7.5 亿元的自有资金进行委托理财。上述额度 可滚动使用，有效期自股东会审议通过之日起不超过 12 个月，并授权公司管理 层具体实施相关事宜。公司根据上述决议，择机购买了相关理财产品，现将有关 情况公告如下： 一、理财产品的主要情况 （一）2025 年 9 月 5 日，全资子公司武汉雅安投资管理有限公司（以下简 称"雅安投资"）出资 1600 万元，向国泰海通证券股份有限公司（以下简称"国 泰海通"）购买理财产品，具体情况如下： 1、产品名称：国泰海通私客尊享 F0F7063 号单一资产管理计划 2、产品代码：955 ...

Core Viewpoint - The announcement from Yong'an Pharmaceutical indicates that the actual controller and chairman, Chen Yong, has had his detention measures lifted, allowing him to resume normal duties, which is expected to stabilize the company's management [2][4]. Group 1: Company Background - Yong'an Pharmaceutical is a leading enterprise in the taurine industry, primarily engaged in the research, production, and sales of taurine products, health foods, and special dietary foods [6]. - The company holds approximately 50% of the global market share in taurine production, with an annual production capacity of 58,000 tons, making it a key supplier for major global brands like Red Bull, Nestlé, and Coca-Cola [6]. Group 2: Financial Performance - The company's financial performance has shown a downward trend, with revenues decreasing from 1.462 billion yuan in 2022 to 839 million yuan in 2024, and net profits declining from 133 million yuan to a loss of 28.41 million yuan during the same period [7]. - In the first half of the current year, Yong'an Pharmaceutical reported revenues of 367 million yuan, a year-on-year decline of 13.7%, and a net profit of 8.55 million yuan, down 83% compared to the previous year [7]. Group 3: New Business Prospects - The company is focusing on the development of creatine products, which are still in the early stages and unlikely to significantly boost performance in the short term [9]. - Yong'an's subsidiary, Ling'an Technology, is undergoing a business transformation to develop monohydrate creatine, leveraging existing production and sales channels to enhance growth potential [9]. - Investors are particularly interested in whether Chen Yong's return will help the company overcome its performance challenges and if the new business initiatives can serve as a growth engine [9].

Group 1 - The graphite electrode sector saw a rise of 5.26%, ranking 8th among concept sectors, with 23 stocks increasing in value, including Shangtai Technology and Putailai hitting the daily limit [1] - Notable gainers in the sector included Beiterui, Daoshi Technology, and Yicheng New Energy, which rose by 19.03%, 10.29%, and 9.09% respectively [1] - The sector experienced a net inflow of 9.62 billion yuan from main funds, with 17 stocks receiving net inflows, and 8 stocks exceeding 50 million yuan in net inflow [2] Group 2 - Shangtai Technology led the net inflow with 1.98 billion yuan, followed by Putailai, Shanshan Co., and Suotong Development with net inflows of 1.77 billion yuan, 1.56 billion yuan, and 861.67 million yuan respectively [2] - The top stocks by net inflow ratio included Shangtai Technology, Longjiang Transportation, and Yunmei Energy, with ratios of 19.19%, 11.45%, and 11.11% respectively [3] - The trading performance of key stocks in the graphite electrode sector showed significant activity, with Shangtai Technology and Putailai both achieving notable price increases and trading volumes [4]

该公告介绍，公司于2021年12月召开第六届董事会第四次会议，审议通过了《关于扩建年产4万吨牛磺 酸食品添加剂项目的议案》，同意公司使用自有资金2.5亿元人民币扩建年产4万吨牛磺酸食品添加剂项 目。2023年2月2日，公司披露了《关于取得年产4万吨牛磺酸食品添加剂扩建项目安评环评批复的公 告》(公告编号：2023-07)，该项目已取得安评环评批复。 据永安药业（002365）(002365.SZ)9月4日公告，公司收到董事长陈勇家属的通知，鹤峰县监察委员会 已解除对陈勇的留置措施，目前陈勇已能正常履行公司董事长的职责。 永安药业总部位于湖北潜江，主营牛磺酸生产制造，牛磺酸是一种含硫的非蛋白质氨基酸，对大脑、眼 睛和心脏的发育与功能至关重要，常常被用于药物和保健食品。据公司2024年年报，永安药业已成为全 球最大的牛磺酸生产基地，占50%左右的市场份额，现已具备牛磺酸生产能力5.8万吨/年，公司亦是红 牛、雀巢、可口可乐等公司的重要供应商。 2025年5月6日，公司公告称陈勇被鹤峰县监察委员会立案调查并实施留置，其子陈子笛代为履行公司董 事长的职责，一时间成为市场关注的焦点。与此同时，永安药业股价似乎并未受到管 ...

9月3日晚间，潜江永安药业（002365）股份有限公司(以下简称"永安药业")发布公告称，公司实际控制 人、董事长陈勇已解除留置措施，目前已能正常履行职责，公司生产经营情况正常，此前代为履行董事 长职责的陈子笛也完成了过渡任务。作为牛磺酸生产龙头企业，近年来，永安药业的营收表现并不乐 观。伴随着陈勇的回归，永安药业能否在巩固牛磺酸龙头地位的同时，拓展新业务领域以挽救其承压的 业绩？ 陈勇已正常履职 回溯事件脉络，今年5月，永安药业发布公告，公司实际控制人、董事长陈勇收到由鹤峰县监察委员会 签发的《立案通知书》和《留置通知书》，陈勇被立案调查并被实施留置。不过，永安药业未明确披露 具体原因，仅表示公司已对相关工作进行了妥善安排。截至目前，公司其他董事、监事和高级管理人员 均正常履职，公司控制权未发生变化，公司生产经营情况正常，上述事项不会对公司日常经营活动产生 重大影响。 公开资料显示，陈勇出生于1959年1月，硕士学历。他曾先后在湖北摩托车厂、黄州市医药化工厂任 职，1995年11月创建黄冈永安药业有限公司(以下简称黄冈永安)，2001年作为主要发起人，在潜江市泽 口经济技术开发区成立永安药业，目前持股比例为 ...

归母净利润已连续两个年度上半年实现下降，2023年-2024年上半年，其归母净利润分别为0.56亿元、 0.52亿元，同比分别下降51.86%、6.49%。 业绩的下降受多重因素的影响。聚焦今年上半年，永安药业解释道，受市场行情低迷影响，上半年公司 主营产品牛磺酸产销量及销售价格比去年同期都有所下降，公司业绩承压。 报告期内，牛磺酸实现收入2.36亿元，占营业收入的64.14%。而2024年上半年，牛磺酸业务收入实现 3.42亿元，同比增长10.25%，占营业收入的80.24%。 从销量层面看，2024年上半年达2.51万吨，今年上半年为2.05万吨，同比下降18.33%。牛磺酸的毛利率 为也有所下降，今年上半年为15.12%，同比降低13.39%。 永安药业于2001年由陈勇作为主要发起人成立，目前主要生产销售食品及药品添加剂牛磺酸、环氧乙烷 及减水剂相关产品、保健品。自2006年起，陈勇开始任职公司董事长，目前，其直接、间接持有公司 25.11%的股份，为最大股东。 2025年5月，陈勇被鹤峰县监察委员会立案调查并实施留置，其子陈子笛代为履行公司董事长的职责。 近四个月后，陈勇被解除留置，管理层的动荡暂时 ...

Group 1 - The actual controller and chairman of Yong'an Pharmaceutical, Chen Yong, has had his detention lifted, allowing him to resume his duties, which enhances investor confidence in the company's future development [1] - FTSE Russell announced the inclusion of BeiGene and WuXi AppTec in the FTSE China A50 Index, reflecting the increasing importance of A-share companies in the global capital market and foreign investment interest in China's innovative drug sector [2] - Otsuka Pharmaceutical's application for the targeted drug, Belimumab injection, for IgA nephropathy has been accepted, potentially filling a market gap in a field with limited treatment options and providing a new growth point for the company [3] Group 2 - Ruizhi Pharmaceutical announced a partnership to establish a fund focused on investing in innovative drugs and medical devices, which will enhance the company's resource reserves and align with current industry trends [4] - Menova's subsidiary has received approval for Mosapride Citrate Tablets in China, which is expected to generate new revenue growth for the company and strengthen its position in the pharmaceutical industry [5]

Group 1 - The overseas investment enthusiasm for Chinese stock ETFs has surged, with significant net inflows recorded in August [4][5] - Five major Chinese stock ETFs have reached a combined asset scale of $26.6 billion, marking an increase of approximately $2.3 billion, or nearly 10%, since the end of July [5] - The inflow is particularly strong for technology-related ETFs, indicating a positive outlook from international investors towards Chinese assets [4] Group 2 - The People's Bank of China and the Ministry of Finance have emphasized the importance of coordinated fiscal and monetary policies to support economic recovery [3] - The meeting highlighted the achievements of the joint working group established last year and discussed various topics including government bond issuance and offshore RMB bond mechanisms [3] Group 3 - The data factor market in China is rapidly developing, with over 500 digital technology companies established by central enterprises [8][9] - The market potential is significant, with predictions that the data factor market will exceed 200 billion yuan this year [9] Group 4 - The real estate market is expected to see increased activity during the "Golden September and Silver October" period, with various promotional events and policies aimed at stabilizing the market [10] - This year's events are characterized by longer durations and a wider variety of participating companies, reflecting stronger support for the market [10] Group 5 - The A-share market is experiencing fluctuations, with the Shanghai Composite Index closing at 3813.56 points, down 1.16% [20] - The Hong Kong stock market also showed a downward trend, with major indices declining [21] Group 6 - Companies like SF Holding and Taiji Group have initiated share buybacks, reflecting confidence in their stock performance [24][25] - Iron Flow Co. has signed a framework agreement with a robotics research institute to enhance its capabilities in robot component design and manufacturing [26]

潜江永安药业股份有限公司 证券代码：002365 证券简称：永安药业 公告编号：2025-50 登录新浪财经APP 搜索【信披】查看更多考评等级 公司指定信息披露媒体为《证券时报》、《中国证券报》、《上海证券报》和巨潮资讯网，公司发布的 信息均以在上述媒体刊登的公告为准。敬请广大投资者注意投资风险。 特此公告。 潜江永安药业股份有限公司 董 事 会 二〇二五年九月三日 关于公司实际控制人、董事长解除留置的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 潜江永安药业股份有限公司（以下简称"公司"）于2025年5月6日披露《关于公司实际控制人、董事长被 留置的公告》（公告编号：2025-31），公司实际控制人、董事长陈勇先生被鹤峰县监察委员会立案调 查并实施留置。 近日，公司收到陈勇先生家属的通知，其收到鹤峰县监察委员会出具的《解除留置通知书》，鹤峰县监 察委员会已解除对陈勇先生的留置措施。目前，陈勇先生已能正常履行公司董事长的职责，公司生产经 营情况正常。陈子笛先生将不再代为履行公司董事长的职责。 ...

近日，永安药业管理层在接受机构调研时表示，公司主要产品牛磺酸采用自行独创工艺，拥有多项发明 及实用新型专利，与同类产品相比具有价格、质量、品牌等竞争优势。未来，公司将深化核心技术研 发，不断提升核心竞争力。 2025年5月5日晚，永安药业公告陈勇被立案调查并实施留置。资料显示，永安药业在牛磺酸行业深耕多 年，已成为全球最大的牛磺酸生产基地，市场份额50%左右，产品广泛出口至世界各地，雀巢、可口可 乐等世界级公司均为该公司客户。 2025年上半年，永安药业营收3.674亿元，同比下滑13.72%；净利润1250万元，同比下滑76.19%。永安 药业表示，受市场行情低迷影响，上半年公司主营产品牛磺酸产销量及销售价格比去年同期都有所下 降，导致业绩承压。 被留置约4个月后，永安药业（002365）实控人、董事长陈勇解除留置措施。 9月3日晚，永安药业披露，近日，公司收到陈勇家属通知，其收到鹤峰县监察委员会出具的《解除留置 通知书》，鹤峰县监察委员会已解除对陈勇的留置措施。目前，陈勇已能正常履行公司董事长职责，公 司生产经营情况正常。陈子笛将不再代为履行公司董事长的职责。 ...